The Latest in CLL

CK doesn’t seem to affect OS in CLL patients taking idelalisib

September 5, 2019

Calquence earns breakthrough designation for CLL monotherapy

August 27, 2019

Zanubrutinib may be poised to challenge ibrutinib for CLL

August 15, 2019

ICYMI: Ibrutinib/rituximab combo improves CLL survival

July 31, 2019

BTK mutations linked to CLL progression on ibrutinib

July 24, 2019

FDA approves rituximab biosimilar for cancer, autoimmune disorders

July 23, 2019

Ibrutinib-venetoclax found highly active in hard-to-treat CLL

July 22, 2019

Potential improvements in convenience, tolerability of hematologic treatment

July 19, 2019

CLL

Acalabrutinib extends PFS in advanced CLL

July 11, 2019

Ibrutinib tops chlorambucil against CLL

July 10, 2019

Hedgehog signaling offers prognostic, therapeutic potential in CLL

June 25, 2019

Fixed-duration venetoclax-obinutuzumab superior to standard CLL therapy

June 7, 2019

Venetoclax plus ibrutinib appears to suit elderly and high-risk patients with CLL

May 29, 2019

Genetic analysis identifies prognostic markers in CLL

May 28, 2019

FDA approves venetoclax/obinutuzumab combo for CLL

May 15, 2019